These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15357973)

  • 1. Ligand conformation has a definitive effect on 5-HT1A and serotonin reuptake affinity.
    Boy KM; Dee M; Yevich J; Torrente J; Gao Q; Iben L; Stark A; Mattson RJ
    Bioorg Med Chem Lett; 2004 Sep; 14(17):4467-70. PubMed ID: 15357973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of novel pyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT
    Ślifirski G; Król M; Kleps J; Ulenberg S; Belka M; Bączek T; Siwek A; Stachowicz K; Szewczyk B; Nowak G; Bojarski A; Kozioł AE; Turło J; Herold F
    Eur J Med Chem; 2019 Mar; 166():144-158. PubMed ID: 30703658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors.
    Deskus JA; Epperson JR; Sloan CP; Cipollina JA; Dextraze P; Qian-Cutrone J; Gao Q; Ma B; Beno BR; Mattson GK; Molski TF; Krause RG; Taber MT; Lodge NJ; Mattson RJ
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3099-104. PubMed ID: 17391962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 1.
    Takeuchi K; Kohn TJ; Honigschmidt NA; Rocco VP; Spinazze PG; Koch DJ; Nelson DL; Wainscott DB; Ahmad LJ; Shaw J; Threlkeld PG; Wong DT
    Bioorg Med Chem Lett; 2003 Jun; 13(11):1903-5. PubMed ID: 12749894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity, part 1.
    Herold F; Chodkowski A; Izbicki Ł; Król M; Kleps J; Turło J; Nowak G; Stachowicz K; Dybała M; Siwek A
    Eur J Med Chem; 2009 Apr; 44(4):1710-7. PubMed ID: 18995929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncotoxic Properties of Serotonin Transporter Inhibitors and 5-HT
    Walory J; Mielczarek L; Jarończyk M; Koronkiewicz M; Kossakowski J; Bugno R; Bojarski AJ; Chilmonczyk Z
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of new 4-butyl-arylpiperazine-3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives and evaluation for their 5-HT
    Wróbel MZ; Chodkowski A; Marciniak M; Dawidowski M; Maksymiuk A; Siwek A; Nowak G; Turło J
    Bioorg Chem; 2020 Apr; 97():103662. PubMed ID: 32086055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of selective serotonin reuptake inhibitor and 5-HT1A antagonist activity in 8-aza-bicyclo[3.2.1]octane derivatives of 2,3-dihydro-1,4-benzodioxane.
    Gilbert AM; Stack GP; Nilakantan R; Kodah J; Tran M; Scerni R; Shi X; Smith DL; Andree TH
    Bioorg Med Chem Lett; 2004 Jan; 14(2):515-8. PubMed ID: 14698193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives, with dual action at 5-HT1A serotonin receptors and serotonin transporter, as a new class of antidepressants.
    Martínez-Esparza J; Oficialdegui AM; Pérez-Silanes S; Heras B; Orús L; Palop JA; Lasheras B; Roca J; Mourelle M; Bosch A; Del Castillo JC; Tordera R; Del Río J; Monge A
    J Med Chem; 2001 Feb; 44(3):418-28. PubMed ID: 11462981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT(1A) activity. part 3.
    Herold F; Chodkowski A; Izbicki Ł; Turło J; Dawidowski M; Kleps J; Nowak G; Stachowicz K; Dybała M; Siwek A; Mazurek AP; Mazurek A; Pluciński F
    Eur J Med Chem; 2011 Jan; 46(1):142-9. PubMed ID: 21093118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity. Part 4.
    Chodkowski A; Wróbel MZ; Turło J; Kleps J; Siwek A; Nowak G; Belka M; Bączek T; Mazurek AP; Herold F
    Eur J Med Chem; 2015 Jan; 90():21-32. PubMed ID: 25461308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Further studies on conformationally constrained tricyclic tropane analogues and their uptake inhibition at monoamine transporter sites: synthesis of (Z)-9-(substituted arylmethylene)-7-azatricyclo[4.3.1.0(3,7)]decanes as a novel class of serotonin transporter inhibitors.
    Zhang A; Zhou G; Hoepping A; Mukhopadhyaya J; Johnson KM; Zhang M; Kozikowski AP
    J Med Chem; 2002 Apr; 45(9):1930-41. PubMed ID: 11960503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia.
    Yan Y; Zhou P; Rotella DP; Feenstra R; Kruse CG; Reinders JH; van der Neut M; Lai M; Zhang J; Kowal DM; Carrick T; Marquis KL; Pausch MH; Robichaud AJ
    Bioorg Med Chem Lett; 2010 May; 20(9):2983-6. PubMed ID: 20347298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and antidepressant-like activity of novel aralkyl piperazine derivatives targeting SSRI/5-HT
    Gu ZS; Zhou AN; Xiao Y; Zhang QW; Li JQ
    Eur J Med Chem; 2018 Jan; 144():701-715. PubMed ID: 29291438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia.
    Rotella DP; McFarlane GR; Greenfield A; Grosanu C; Robichaud AJ; Denny RA; Feenstra RW; Núñez-García S; Reinders JH; Neut Mv; McCreary A; Kruse CG; Sullivan K; Pruthi F; Lai M; Zhang J; Kowal DM; Carrick T; Grauer SM; Navarra RL; Graf R; Brennan J; Marquis KL; Pausch MH
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5552-5. PubMed ID: 19720528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microwave-Assisted Synthesis of Trazodone and Its Derivatives as New 5-HT
    Jaśkowska J; Zaręba P; Śliwa P; Pindelska E; Satała G; Majka Z
    Molecules; 2019 Apr; 24(8):. PubMed ID: 31018618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity: part 2.
    Herold F; Izbicki Ł; Chodkowski A; Dawidowski M; Król M; Kleps J; Turło J; Wolska I; Nowak G; Stachowicz K; Dybała M; Siwek A; Nowak M; Pieniazek E; Jarończyk M; Sylte I; Mazurek AP
    Eur J Med Chem; 2009 Nov; 44(11):4702-15. PubMed ID: 19665823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidepressant treatment reduces serotonin-1A autoreceptor binding in major depressive disorder.
    Gray NA; Milak MS; DeLorenzo C; Ogden RT; Huang YY; Mann JJ; Parsey RV
    Biol Psychiatry; 2013 Jul; 74(1):26-31. PubMed ID: 23374637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
    Orjales A; Mosquera R; Toledo A; Pumar MC; García N; Cortizo L; Labeaga L; Innerárity A
    J Med Chem; 2003 Dec; 46(25):5512-32. PubMed ID: 14640559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of Adult 5-HT1A Autoreceptors Results in a Paradoxical Anxiogenic Response to Antidepressant Treatment.
    Turcotte-Cardin V; Vahid-Ansari F; Luckhart C; Daigle M; Geddes SD; Tanaka KF; Hen R; James J; Merali Z; Béïque JC; Albert PR
    J Neurosci; 2019 Feb; 39(8):1334-1346. PubMed ID: 30552180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.